What are CJC-1295 and Ipamorelin and how do they work together?

CJC-1295 and Ipamorelin are growth hormone secretagogues - peptides that stimulate the body to release its own growth hormone rather than providing synthetic GH directly. CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH) with extended half-life due to DAC (Drug Affinity Complex) modification. It stimulates the pituitary to release growth hormone pulses. Ipamorelin is a growth hormone-releasing peptide (GHRP) that works through the ghrelin receptor to trigger GH release. Used together, they provide synergistic effects - CJC-1295 increases baseline GH levels while Ipamorelin amplifies pulses. Potential benefits include: improved body composition (reduced fat, increased lean mass), better recovery, enhanced sleep quality, and anti-aging effects. Typical dosing involves CJC-1295 at 1-2 mg weekly and Ipamorelin at 100-300 mcg daily, often before bed to align with natural GH secretion patterns. These peptides are not FDA-approved and are primarily used in anti-aging and performance optimization communities based on research rather than clinical trial data.